Welcome to Beacon Equity Research. Today is Sunday, 30 December 2007  
 Home     Covered Companies     News and Commentary     Our Team     Ratings     Contact Us     Charity     Affiliates    

Beacon Research Issues TraderNotes on SDVI, SYDI, PPHM, NANX, CPST for December 28, 2007

Today’s TraderNotes include: Signature Devices, Inc. (Pink Sheets: SDVI), Syndication Inc. (OTCBB: SYDI), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Nanophase Technologioes Corporation (Nasdaq: NANX), Capstone Turbine Corporation (Nasdaq: CPST)


Signature Devices, Inc. (SDVI) TraderNote - SDVI Boosted by Open Market Purchase of 1.3M Shares by Its CEO


Signature Devices, Inc. (SDVI) closed yesterday at 0.07, a positive change of 0.01 or an increase of 30.00% from the previous close of 0.05. Signature Devices, Inc. creates, develops and manufactures advanced information technology, including computer systems, software and electronics products. One of the company's premiere technologies includes a blend of hardware and software for Image generation technology used in video games and simulations. Signature Devices also owns Graffiti Entertainment, LLC, a publisher of interactive entertainment software for advanced entertainment consoles. Recently, Signature Devices CEO Kenneth Hurley bought 1.3 million shares of the company in open market purchases. This brings his total common stock holdings in Signature Devices, Inc. to 23,785,532 shares. In yesterday’s trading, SDVI heavily traded with a volume of 2,349,896 shares following the open market purchase by the CEO of 1.3M shares the previous day.  Slow Stochastics indicator in yesterday’s daily chart reflected readings of 22.10 %K and 18.70 %D curving upwards crossing the 20% level, signaling an oversold condition or buying potential.


Syndication Inc. (SYDI) TraderNote – SYDI Expands Its Locations, Spinal Decompression Division and Increases Number of Doctors


Syndication Inc. (SYDI) closed yesterday at 0.0009, a positive change of 0.0006 or a tremendous increase of 200% from the previous close of 0.0003. Syndication, Inc. is a development stage consulting company which acquires controlling interests in or to participate in the creation of, and to provide financial, management, and technical support to development stage businesses, e-commerce businesses, and traditional brick-and-mortar businesses. The company assists target companies in various capacities, including the development and implementation of business models to provide solutions to traditional companies; building corporate infrastructure; managing rapid growth; evaluating and negotiating corporate transactions; and providing advice relating to corporate finance, financial reporting, and accounting operations. Syndication Inc., through its wholly owned subsidiary Sy-Med Spinal Decompression Inc., is currently expanding its locations and the number of Doctors in its marketing network. SYDI will also be expanding its Spinal Decompression division in 2008. In yesterday’s trading, SYDI heavily traded with a volume of 132,787,564 shares within the range of 0.0004 – 0.0015.  Yesterday’s daily chart reflected a bullish signal in the MACD indicator as the 12-day exponential moving average (EMA) was trading above the 26-day EMA after an immediate crossover between the two lines.


Peregrine Pharmaceuticals, Inc. (PPHM) TraderNote – PPHM Well-Positioned with Its Portfolio of Therapeutics and Wide Range of Contract Manufacturing Services


Peregrine Pharmaceuticals, Inc. (PPHM) closed yesterday at 0.43, a positive change of 0.06 or an increase of 15.85% from the previous close of 0.38. Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the research, development, and commercialization of therapeutics for cancer and viral diseases. It develops a portfolio of clinical and preclinical stage monoclonal antibody-based targeted therapeutics, including bavituximab that is in a multi center Phase I clinical trial for the treatment of solid cancers, as well as in multi center Phase Ib clinical trial for the treatment of chronic HCV infection under its anti-phosphatidylserine immunotherapeutic technology platform. In addition, Peregrine, through its wholly owned subsidiary, Avid Bioservices, Inc., provides a range of contract manufacturing services, including contract manufacturing of antibodies and proteins, cell culture development, process development, and testing of biologics for biopharmaceutical and biotechnology companies.  In yesterday's trading, PPHM traded a volume of 1,755,861 shares within the range of 0.35 – 1.40.  Yesterday's daily chart reflected an almost neutral territory with near even readings for the 12-day and 26-day EMAs at -0.033 and -0.032, respectively.  RSI was in the bearish zone at 45.39 but with a potential bullish direction towards the 50% threshold.  Slow Stochastics indicated an oversold condition with readings rising above the 20% level at 28.04 %K and 25.33 %D, reflecting a potential buying signal.


Nanophase Technologies Corporation (NANX) TraderNote – NANX Gains Growth Potential from Its New Line of Engineered Nanomaterial Dispersions


Nanophase Tehcnologies Corporaion (NANX) closed yesterday at 4.14, a positive change of 0.56 or an increase of 15.64% from the previous close of 3.58. Nanophase Technologies Corporation engages in the development, manufacture, and sale of nanomaterials in the United States, Europe, and Asia. Nanomaterials are comprised of nanoparticles that are approximately 100 nanometers in diameter. These products are primarily used in sunscreens, personal care, architectural coatings, industrial coating ingredients, plastic additives, water filtration, DNA biosensors, semiconductor polishing, optics polishing, and other markets. Nanophase Technologies recently announced the availability of innovative nanoengineered dispersions optimized for water-based coatings, which new line helps achieve the goal of paint and coating manufacturers to increase the scratch resistance and gloss retention of water-based systems to be equal to oil-based organic systems.  In yesterday’s trading, NANX traded a volume of 636,277 shares within the range of 3.48 – 4.48. Yesterday’s move was an expected breakout from a previous positive divergence established in the stock's daily chart MACD histogram for the first week of December to middle of the month. RSI also reflected a bullish signal as it continued to climb the 59.70 level in yesterday's trade.


Capstone Turbine Corporation (CPST) TraderNote – CPST Potentially Strengthened by Demand for Its New C65 Liquid Fueled Microturbine by DoCoMo Engineering Shikoku Inc. of Japan


Capstone Turbine Corporation (CPST) heavily traded yesterday with a volume of 4,177,525 shares within the range of 1.69 – 1.83.  Capstone Turbine Corporation engages in the development, manufacture, marketing, and service of microturbine technology solutions. Its solutions are primarily used in stationary distributed power generation applications, including cogeneration, resource recovery, and secure power. The company's solutions can also be used as generators for hybrid electric vehicle applications. It sells microturbine units, subassemblies, components, and various accessories. It recently announced that it received the first order for its new C65 liquid fueled microturbine from DoCoMo Engineering Shikoku Inc. (NTT DoCoMo Group), Japan’s premier mobile communications company. The order is for two microturbines for system integration and they are scheduled to ship early next spring.  In yesterday’s trading, CPST closed at 1.69, a slight negative change of 0.08 or a decrease of 4.52% from the previous close of 1.77.  Yesterday's daily chart reflected readings of 0.118 and 0.093, respectively for the 12-day and 26-day EMAs, indicating a near-term bullish signal as the gap between the two is widening, with a positive and rising MACD.


Beacon Equity Research Disclosure


The analysts contributing to this report do not hold any shares of Signature Devices, Inc. (SDVI).  Additionally the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research (“Beacon”) certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report.  Beacon Equity Research and its affiliates have been directly compensated six hundred thousand shares from TI Consulting for enrollment of SDVI in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
Next >

Copyright 2007 Beacon Equity Research